Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), sold 39,164 shares at $45.57 ($1.8M) on 2022-12-30, disclosed to the SEC on 2023-01-03.
Open-market sale of $1.8M RARE by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.57 | 19,582 | $892K | 50.0% |
| 2 | $45.57 | 19,582 | $892K | 50.0% |
| Total | $45.57 avg | 39,164 | $1.8M | 100% |
| Filing → |
| RARE | SELL | 2024-12-31 | $990K | — | Filing → |
| RARE | SELL | 2024-12-11 | $414K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |